Drug Discovery

Bayer and Loxo Oncology to develop and commercialize two cancer therapies

Bayer has entered into an exclusive global collaboration with Loxo Oncology for the development and commercialization of larotrectinib (LOXO-101) and LOXO-195.

Research indicates potential treatment for autism and intellectual disability

A University of Nebraska Medical Center researcher and his team at the Munroe-Meyer Institute (MMI) made a breakthrough in finding the mechanism and a possible therapeutic fix for autism and intellectual disability

Sanofi to develop Principia’s MS drug candidate in $805m deal

Sanofi has agreed to develop Principia Biopharma’s Bruton’s tyrosine kinase (BTK) inhibitor (PRN2246) for the treatment of multiple sclerosis (MS) and possibly other central nervous system (CNS) diseases.

Cerenis Therapeutics acquires Lypro Biosciences

Cerenis Therapeutics has acquired Lypro Biosciences to expanding its HDL strategy into immuno-oncology and chemotherapeutic drug delivery.

Spark Therapeutics, Pfizer amend license deal for investigational SPK-9001 in hemophilia B

Spark Therapeutics and Pfizer have entered into an amendment to their license agreement for SPK-9001, an investigational gene therapy for hemophilia B.

Recursion Pharmaceuticals uses Splunk machine learning to treat genetic diseases

Biotechnology company Recursion Pharmaceuticals is using Splunk Enterprise and the Splunk Machine Learning Toolkit to reach its target of treating 100 molecular genetic diseases by 2025.

Boehringer, Dicerna partner on RNAi treatment for NASH

Boehringer Ingelheim and Dicerna Pharmaceuticals have partnered to develop treatments for chronic liver diseases including Nonalcoholic Steatohepatitis (NASH).

Aviragen Therapeutics and Vaxart sign merger deal

Aviragen Therapeutics, which is engaged in the discovery and development of direct-acting antivirals to treat infections with limited therapeutic options, has signed a merger agreement with Vaxart, a clinical-stage company focused on developing oral recombinant vaccines.

Voyager to gain global rights to VY-AADC program for advanced Parkinson’s disease

Voyager Therapeutics, a clinical-stage gene therapy company focused on developing treatments for severe neurological diseases, has announced an update to its VY-AADC program for advanced Parkinson’s disease.